Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of <i>Helicobacter pylori</i>: A Real-World Evidence Study

雷贝拉唑 医学 耐受性 幽门螺杆菌 内科学 胃肠病学 阿莫西林 克拉霉素 意向治疗分析 不利影响 抗生素 微生物学 生物
作者
Yoon Suk Jung,Sun Yong Kim,Hyun-Young Kim,Seung Jae Noh,Jung Ho Park,Chong Il Sohn,Chan Hyuk Park
出处
期刊:Gut and Liver [Korean Association for the Study of the Liver]
标识
DOI:10.5009/gnl220218
摘要

Tegoprazan, a new, fast, and strong potassium-competitive acid blocker, has been approved for the treatment of gastric acid-related diseases in Korea. However, real-world clinical data regarding this drug are scarce. We aimed to compare the Helicobacter pylori eradication rates of tegoprazan- and rabeprazole-based triple therapy.We retrospectively reviewed data from patients who received first-line treatment for H. pylori infection using tegoprazan- or rabeprazole-based triple therapy for 2 weeks (50 mg tegoprazan or 20 mg rabeprazole+1,000 mg amoxicillin+500 mg clarithromycin twice daily). The primary endpoint was the eradication rate as determined by intention-to-treat analysis.Of the 677 patients included in our study, 344 and 333 received tegoprazan-based and rabeprazole-based triple therapy, respectively. The eradication rate from intention-to-treat analysis was 76.7% (95% confidence interval [CI], 72.1% to 81.0%) for tegoprazan-based triple therapy and 75.4% (95% CI, 70.5% to 79.8%) for rabeprazole-based triple therapy. There was no significant difference in the eradication rates between the two groups (p>0.999). Per-protocol analysis also revealed no significant difference between the eradication rates of the two groups (tegoprazan 83.4% [95% CI, 79.0% to 87.2%] vs rabeprazole 83.5% [79.0% to 87.4%], p>0.999). Furthermore, there was no significant difference in adverse event rates between the two groups (tegoprazan, 27.6%; rabeprazole, 25.8%; p=0.604).The eradication rate of tegoprazan-based triple therapy was similar to that of rabeprazole-based triple therapy. Further studies on the dose-escalation effect of tegoprazan for H. pylori eradication and the efficacy of tegoprazan in regimens other than conventional triple therapy are needed.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lqy发布了新的文献求助10
刚刚
英俊的铭的应助被科研通管家采纳,获得10
刚刚
科研通AI6.3的应助被JZCT采纳,获得10
刚刚
刚刚
刚刚
CipherSage的应助被科研通管家采纳,获得10
刚刚
酷波er的应助被科研通管家采纳,获得10
刚刚
烟花的应助被乌冬面采纳,获得10
刚刚
刚刚
Earuan的应助被科研通管家采纳,获得10
刚刚
天天向上的应助被可可萝oxo采纳,获得10
刚刚
华仔的应助被科研通管家采纳,获得10
刚刚
合适南霜完成签到,获得积分10
1秒前
1秒前
无花果的应助被科研通管家采纳,获得10
1秒前
1秒前
大个的应助被科研通管家采纳,获得10
1秒前
小二郎的应助被科研通管家采纳,获得10
1秒前
ZUOSG完成签到,获得积分10
1秒前
极限001的应助被科研通管家采纳,获得30
1秒前
1秒前
1秒前
Owen的应助被科研通管家采纳,获得10
2秒前
2秒前
wyh123完成签到,获得积分10
2秒前
2秒前
皮不可发布了新的文献求助10
2秒前
2秒前
2秒前
2秒前
wanci的应助被老张采纳,获得10
2秒前
2秒前
pss完成签到,获得积分10
3秒前
elephant发布了新的文献求助10
3秒前
3秒前
3秒前
3秒前
喜悦雪曼完成签到,获得积分20
3秒前
123发布了新的文献求助10
3秒前
4秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175943
求助须知:如何正确求助?哪些是违规求助? 9567501
关于积分的说明 21793186
捐赠科研通 7770490
什么是DOI,文献DOI怎么找? 3431935
关于科研通互助平台的介绍 2556294
邀请新用户注册赠送积分活动 2477485